Chester County News and Community Website
PHILADELPHIA, PA — Century Therapeutics Inc. (Nasdaq: IPSC) will meet with investors at the Jefferies Global Healthcare Conference in London on November 18, as the Philadelphia biotechnology company advances experimental …
Century Therapeutics Seeks Investor Meetings at London Conference Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) remains on track to seek U.S. clearance in the fourth quarter to begin clinical testing of CNTY-813, its experimental type 1 diabetes …
Century Advances Diabetes Cell Therapy Toward FDA Filing Read More PHILADELPHIA, PA — Century Therapeutics Inc. (Nasdaq: IPSC) appointed biotechnology executive Joseph Truitt to its board as the company prepares to move two cell-therapy programs toward regulatory and clinical milestones …
Century Adds Biotech Veteran as Cell Therapies Near Milestones Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) is targeting a fourth-quarter 2026 regulatory filing for its experimental type 1 diabetes cell therapy after reaching general alignment with the U.S. …
Century Targets FDA Filing for Diabetes Cell Therapy Read More PHILADELPHIA, PA — Century Therapeutics (NASDAQ: IPSC) will present new data on its experimental type 1 diabetes cell therapy at two scientific conferences this fall, a step that comes as …
Century Therapeutics Advances Diabetes Program With Conference Talks Read More PHILADELPHIA, PA — Century Therapeutics (Nasdaq: IPSC) reported new preclinical data supporting its experimental type 1 diabetes therapy CNTY-813, as the biotechnology company works toward a planned Investigational New Drug …
Century Therapeutics Advances Diabetes Cell Therapy Toward 2026 FDA Filing Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (Nasdaq: IPSC) said it remains on track to seek regulatory clearance next year for its experimental type 1 diabetes cell therapy as the company …
Century Advances Diabetes Cell Therapy Toward Human Trials Read More PHILADELPHIA, PA — Century Therapeutics Inc. (Nasdaq: IPSC) reported its financial results for 2025 and outlined progress across its pipeline of stem cell-derived therapies, including plans to submit a regulatory …
Century Therapeutics Reports 2025 Results, Advances Cell Therapy Pipeline Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has appointed Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its board of directors, strengthening governance and strategic oversight as the …
Century Therapeutics Adds Veteran Deal-Makers to Board as Pipeline Nears Clinic Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has unveiled its first program targeting Type 1 diabetes, introducing an engineered cell therapy designed to restore natural insulin production without the …
Century Therapeutics Debuts Immune-Evasive Cell Therapy Aiming to Transform Type 1 Diabetes Read More